APA (7th ed.) Citation

Yang, J. C., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., . . . Cho, B. C. (2025). Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. The New England journal of medicine, 393(17), . https://doi.org/10.1056/NEJMoa2503001

Chicago Style (17th ed.) Citation

Yang, James Chih-Hsin, et al. "Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC." The New England Journal of Medicine 393, no. 17 (2025). https://doi.org/10.1056/NEJMoa2503001.

MLA (9th ed.) Citation

Yang, James Chih-Hsin, et al. "Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC." The New England Journal of Medicine, vol. 393, no. 17, 2025, https://doi.org/10.1056/NEJMoa2503001.